ClinicalTrials.gg
CompletedNCT04796948Updated Apr 29, 2025

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

A Phase 1 interventional study of Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection) in Advanced Pancreatic Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing fluorouracil in Pancreatic Neoplasms — 11 open to participants now, 16 under way, 5 of them phase 3. Fluorouracil · Pancreatic Neoplasms.

Enrollment
48th of 76
41 · median 55
Started
2021
with 3 others
Phase 1
12 of 84
none open now
Registered
73rd of 84
by date
Lead sponsor
2 of 84
Jiangsu HengRui Medicine Co., Ltd.

Among the 84 studies testing fluorouracil in Pancreatic Neoplasms, this one is the 48th largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2021, is one of 12 in phase 1, and was the 73rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

11 of the 84 studies testing fluorouracil in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing fluorouracil in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

03

Conditions studied

  • Advanced Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18 to 70 years (including 18 and 70 years);
  2. Patients with or cytologically diagnosed pancreatic cancer (from pancreatic ductal epithelium), and clinical records show unresectable locally advanced or pancreatic cancer (stage III/IV based on the 8th Edition of the AJCC TNM staging for pancreatic cancer).
  3. Have not received systemic anti-tumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy or therapy;
  4. If the subject has previously received chemotherapy, it is necessary to ensure that the time interval between the last dose and the first dose of this study is more than 12 months, and the adjuvant therapy-toxicity has recovered (judged as ≤ grade 1 based on 5.0 criteria);
  5. Must have at least one that can be taken as the target lesion (according to the v1.1 criteria);
  6. (ECOG) performance status score: 0 - 1 point;
  7. Expected survival ≥3 months;
  8. Major organs are functioning well

Exclusion criteria

Exclusion Criteria:

  1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;
  2. Patients with known central nervous system ;
  3. Patients carrying homozygous mutations of UGT1A1*28/*6 gene;
  4. Severe gastrointestinal dysfunction;
  5. Severe infection (> grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;
  6. Received any of the following treatments:

1)Previously received treatment with irinotecan-containing regimens; 2)Received concomitant medications containing strong inhibitors/strong inducers of or strong inhibitors of UGT1A1 within two weeks before enrollment; 3)Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4)Have received treatment with any other drug/device within four weeks before enrollment; 5)Enrolled in another clinical study at the same time unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up.

7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within one year; (4) supraventricular or ventricular arrhythmia requiring treatment or intervention.

9.Patients who have suffered from malignant tumors other than pancreatic cancer before using the study drug for the first time, except those with low risk of metastasis and death (5-year survival rate >90%), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin; 10.Have any to either irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection)

    1. irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion. 2. oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial. 3. 5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g. 4. LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution.

    Drug: Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection)

Interventions

06

What researchers measure

Primary outcomes

  1. MTD

    Maximum tolerated dose for patients in combination treatment.

    Time frame: 18 months

  2. RP2D

    Recommended phase II dose for patients in combination treatment.

    Time frame: 18 months

Secondary outcomes

  1. Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0

    Through laboratory test, physical examination, vital signs,12-lead electrocardiogram (ECG), Echocardiogram, etc.;

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.

  2. Objective Response Rate (ORR)

    Number of reported responses (complete \[CR\] and partial \[PR\]) divided by the number of reported assessable patients.

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.

  3. Disease Control Rate (DCR)

    Based on investigator reviewed radiographic tumour assessment and death.

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months

  4. Duration of Response (DoR)

    Based on investigator reviewed radiographic tumour assessment and death.

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.

  5. Progression-Free Survival (PFS)

    Based on change in tumour per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.

  6. Overall Survival (OS)

    Based on investigator reviewed radiographic tumor assessment and death.

    Time frame: From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.

  7. Cmax

    peak plasma concentration

    Time frame: 28days

  8. Tmax

    time to peak concentration

    Time frame: 28days

  9. AUC

    area under the plasma concentration versus time curve

    Time frame: 28days

  10. t1/2z

    elimination half-life

    Time frame: 28days

  11. Vss

    steady-state apparent volume of distribution

    Time frame: 28days

  12. CL

    clearance

    Time frame: 28days

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2024, 38 months.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 38 months is below that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 15, 2021
StartActual
Apr 8, 2021
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04796948
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Apr 8, 2021
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Last update
Apr 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorouracil

Start the discussion